Replimune Group announced Sander Slootweg, founder and managing partner at Forbion, will not seek to be reappointed as a non-executive director at the end of his current term at the company’s upcoming annual general meeting.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on REPL:
- Replimune Announces Sander Slootweg will Depart from its Board of Directors
- JPMorgan ups Replimune target to $50, adds to Analyst Focus List
- Biotech Alert: Searches spiking for these stocks today
- Replimune Presents Initial RP1 Data from the ARTACUS Clinical Trial at the 2023 American Transplant Congress (ATC) Meeting
- Replimune Appoints Veleka R. Peeples-Dyer to its Board of Directors